NCT04530110: An ongoing trial by Teva Branded Pharmaceutical Products R&D LLC
This trial is ongoing. It must report results 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04530110 |
|---|---|
| Title | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 16, 2020 |
| Completion date | Aug. 15, 2025 |
| Required reporting date | Aug. 15, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |